Adopting An Integrative Approach to Mental Wellness and Resilience in 2021 – Longevity LIVE

Mental illness seems to be on the rise in modern society. A vital strategy for maintaining a balanced mood, good energy levels, and sound brain connection is to be aware, to be present, and to be open to new ideas, behaviors, and perceptions.

While genetic predisposition certainly increases our risk for mental illness, the following wellness practices can dramatically reduce it:

According to specialist physician and pioneer of aging medicineDr. Craige Golding, there are well-researched alternatives to the overprescribing of chemical drugs to manage mental illness. Micronutrient depletions from the chronic use of pharmaceuticals should also be addressed. An understanding of the major neurotransmitters involved with mood, memory, motivation, sleep and a balanced, healthy mind is required.

The COVID-19 pandemic has highlighted the need for stronger immune systems. We all know that sunlight exposure, vitamin D, and vitamin C are very beneficial for optimum immune system health. Other useful nutrients include zinc and ionophore-type nutrients to get zinc intracellularly, to assist with optimum antiviral protection. These include nutraceuticals such as quercetin and/or egcg (a green tea extract), and resveratrol.

Medicinal mushrooms such as reishi, maitake, and shiitake are also useful for immune support.

Of course, there are many other immune-supportive strategies to consider. This includes exercise and a healthy, balanced diet with a wide variety of colorful foods.

For a healthy immune response against a viral attack, other treatments include:

These help the heat-sensitive viruses become more vulnerable and susceptible.

Golding stresses the importance of good gut function because conditions such as leaky gut or hyperpermeable gut can interfere with the absorption of nutrients. He advises following a five-step program:

Temperature fluctuations place a type of stress on the body that can be helpful. Having a cold shower and then an infrared sauna can be beneficial for physiological adaptation. The idea behind this is that the better you are able to adapt to your conditions, the better your chances of living longer. This relates to your mental resilience and your immune system.

Several kinds of adaptogenic herbs are used to help your adrenals in alternative medicine. Astroganda, for example, originates from certain mountainous plants that regularly experience severe fluctuations in temperature. They have learned to adapt and survive in hot-to-cold conditions.

Golding says caloric restriction, intermittent fasting, and time-restricted eating are all important pro-aging strategies.

The fear of a second wave is impacting how were looking forward to 2021. With that said, here is some advice on how to cope and manage your fears during the second wave.

Excerpt from:
Adopting An Integrative Approach to Mental Wellness and Resilience in 2021 - Longevity LIVE

Global Folding Carton in Healthcare Market (2020 to 2025) – Growth, Trends and Forecasts – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Folding Carton in Healthcare Market - Growth, Trends, Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

The Folding carton market for the Healthcare market is expected to register a CAGR of 5.72% during this forecast period.

Companies Mentioned

Key Market Trends

Growing Emphasis of Monitoring and Assisting Patient Medication

Asia Pacific is the Fastest Growing Region for this Market

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Stringent regulations related to discerning key product related information in the field of medical devices?

4.2.2 Growing emphasis of monitoring & assisting patient medication ?

4.2.3 Focus on traceability & anti-counterfeiting in the healthcare sector

4.2.4 Product & Material-based innovations driven by major packaging manufacturers to drive demand

4.3 Market Challenges

4.4 Market Opportunities

4.5 Key material properties of Folding carton-based secondary packaging materials

4.6 Analysis of the impact of COVID-19 on the Folding Carton in Healthcare industry

5 KEY PRODUCT INNOVATION IN FOLDING CARTON INDUSTRY

6 MAJOR INNOVATIONS IN LEAFLET & INSERT PACKAGING FOR HEALTHCARE

7 MARKET SEGMENTATION

7.1 Product Type

7.1.1 Blisters

7.1.2 Vials & Ampoules

7.1.3 Injectables

7.1.4 Other Product Types (Medical Devices, etc)

7.2 Labelling

7.2.1 Labelling Type?

7.2.1.1 Pressure Sensitive

7.2.1.2 In-Mold ?

7.2.1.3 Shrink-Sleeve

7.2.1.4 Glue-Applied

7.2.1.5 Others (Custom Die-cut, etc.)

7.2.2 Advancements in the Labelling Industry (to include coverage on the growing adoption of digital printing & Flexography Printing)

7.2.3 Key regulations on Medical Device Labelling (FDA, IMRDF, etc.)

7.2.4 Key specific manufacturers in Labelling

7.2.4.1 WS Packaging

7.2.4.2 Schreiner Group

7.2.4.3 Faubel & Co

7.2.4.4 OPM Group

7.3 Geography

7.3.1 North America

7.3.2 Europe

7.3.3 Asia-Pacific

7.3.4 Rest of the World

8 COMPETITIVE LANDSCAPE

8.1 COMPANY PROFILES

9 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/yahj24

Continue reading here:
Global Folding Carton in Healthcare Market (2020 to 2025) - Growth, Trends and Forecasts - ResearchAndMarkets.com - Business Wire

CRYPTOSIS Take You Behind The Scenes Of "Prospect Of Immortality" Music Video – bravewords.com

January 6, 2021, 2 days ago

news heavy metal cryptosis

Dutch futuristic multi-metal eruption, Cryptosis, have released behind the scenes footage from the shoot for their latest video, Prospect Of Immortality. Find the new footage, as well as the official video, below.

On the single, the band stated: "'Prospect Of Immortality' is a song in which we used an experimental approach of songwriting. In contrast to other material, this song is a lot more atmospheric and doesnt make use of a clear verse/chorus structure. The lyrics are written as a suicide note by a person who can no longer cope with the 24/7 surveillance and human experiments that she is being subjected too. The experiments and lost sense of reality has caused her to believe suicide is the only way out. Trapped inside a continuous cycle of endeavours, she is unable to succeed. The song consists of 5 chapters, each representing a different part of her reality."

Check out the previously released video for Decypher:

Cryptosis are:

Laurens Houvast (vocals/guitar)Frank te Riet (bass/mellotron/backing vocals)Marco Prij (drums)

View original post here:
CRYPTOSIS Take You Behind The Scenes Of "Prospect Of Immortality" Music Video - bravewords.com

Phase 4 Introduces A Bigger MCU Problem Than Retiring The OG Avengers – Screen Rant

It will be tricky to retire the remaining original Avengers in Phase 4, but they have a bigger problem with the Eternals who are deemed immortals.

The impending introduction of the Eternals in the Marvel Cinematic Universe poses a bigger problem than how to retire the remaining Avengers. 2019's Avengers: Endgame marked the end of the Infinity Saga with Spider-Man: Far From Home functioning as its epilogue. To further highlight the idea it's the final chapter of the franchise's first overarching narrative, the movie doubled as the swan song to some of its founding heroes such as Iron Man, Captain America, and Black Widow, leavingHulk, Thor, and Hawkeye still in the universe.

By keeping some original heroes, Marvel Studios is slowly transitioning from the Infinity Saga to new storytelling territory in Phase 4. This is the safest way to ensure the MCU continues to be successful without getting stagnant. Seeing some of the founding Avengers still involved in the franchise will help fans get used to this difficult but needed change. Losingprimary players like Iron Man and Captain America isalready jarring as it is, but it would've been a much more difficult transition if all six Avengers were non-existent in MCU's future.

Related:Infinity War Teased Iron Man's Death Well Before The Snap

There will come a time that Hulk, Thor, and Hawkeye will eventually leave the MCU, however; Marvel Studios may already be setting up their imminent departure with the introduction of their respective franchise replacements. Without any massive event like Endgame on thehorizon, it will be difficult to find a justified way to see them off. Even with that, it will still be tricky to write out almost-immortal heroes like Thor and Hulk.That being said, Marvel Studios is setting themselves up for a similar but more difficult problem when they introduce the Eternals to the MCU.Createdby the Celestials,the Eternals are powerful beings who are essentially immortals, meaningthey had to have been in unseen existence in the franchise for centuries now.

At this point, not much is known about these new characters, but soon, they will debut in the MCU through Chloe Zhao's Eternals. There's no explicit indication they've already been in the franchise throughout the Infinity Saga, although the Celestials have been referenced in past films. Considering how they're being set to be very powerful characters, it would be more difficult to find a way to justify their deathswhen their time in the MCU comes to an end,like Iron Man and Captain America in Endgame.Of course, there's always the possibility that by the time they emerged and become prominent key players in the franchise, they're already at the tail end of their life spans since they've been alive for centuries. As seenwithOdin in Thor: Ragnarok, they're not exactly immune to death.

While Kevin Feige and co.are known for playing the long game in the Marvel Cinematic Universe, it's more likely that they don't have anything laid out when it comes to writing out upcoming characters in the franchise. After all, if they go by what they did in the Infinity Saga. most of the Eternals will have at least 10 years in the universe before they move on. In any case,Marvel Studios would need to have a more put-together exit plan for these characters compared to its predecessors considering their origins.

More: Every Time The Infinity Stones Were Used Wrong In The MCU

The Batman: How Robert Pattinson's Batsuit Compares To The Dark Knight

Accidental geek who is perpetually curious, Ana rekindled her love for writing several years back and married it with everything pop culture. The result is a passionate young writer who could ramble (and of course, pen) about films and series multiple hours a day. She has a soft spot for The Lion King, old songs, and home design; is currently obsessed with old sitcoms (The Golden Girls!); and won't dare watch any horror films although shes (ironically) dying to see one. Though a bit late to the party and was an actual Force non-believer, she now finds the Star Wars franchise quite fascinating (fun fact: it was a crazy Jar Jar Binks/Sith theory that drew her in).

View post:
Phase 4 Introduces A Bigger MCU Problem Than Retiring The OG Avengers - Screen Rant

Holocaust Memorial Center hosts ‘Soap Myth’ online reading and discussion – The Detroit News

Award-winning playwright Jeff Cohen is heralding the importance of listening to Holocaust survivors while they're still living.

Actor Ed Asner stars in "The Soap Myth."(Photo: Burke-Cohen Entertainment)

Well-known stage and screen actors Ed Asner and Tovah Feldshuh star in a PBS concert reading of his play, "The Soap Myth," hosted by theHolocaust Memorial Center Zekelman Family Campus. It was filmed last January in New York and is viewable online now.

This Sunday, watch a Zoom conversation between playwright Jeff Cohen and Detroit News film critic Adam Graham.

"The Soap Myth" is set 50 years after the end of World War II and tells the story of an elderly Holocaust survivor,Milton Saltzman, who believes the Nazis turned the fat of murdered Jewish people into soap.

He teams up with a young investigative journalist in hopes that historians and museums recognize his eyewitness account. The play also delves into the evils of antisemitism and Holocaust denial in present day.

"The Soap Myth" reading at B'nai Jeshurun, New York in January 2019, starring Ed Asner and Tovah Feldshuh.(Photo: Burke-Cohen Entertainment)

"In the power of live theater lives a certain immortality," said Cohen in a press release about the virtual performance. "Five years from now, 50 years from now, 150 years from now when an actor portrays Milton Saltzman, Milton is alive. For those 90 minutes, Milton lives in all his rage and all his sorrow and all his stubborn refusal to be silenced. And when Milton lives, rest assured, he will not let the audience forget the Holocaust."

The play's reading is viewable to watch online now atbit.ly/TheSoapMyth-play-on-PBS.

Register in advance for the 2 p.m. Sunday Zoom webinar with Cohen and Graham atbit.ly/TheSoapMyth-HMC-event.Those with questions for Cohen or Graham can submit them by noon Tuesday atholocaustcenter.org/questions.

mbaetens@detroitnews.com

Twitter: @melodybaetens

'The Soap Myth'

Online discussion with playwright Jeff Cohen and Detroit News film critic Adam Graham

2 p.m. Sunday

Register in advance:bit.ly/TheSoapMyth-HMC-event

Concert reading of the play online now:bit.ly/TheSoapMyth-play-on-PBS

Read or Share this story: https://www.detroitnews.com/story/entertainment/2021/01/06/holocaust-memorial-center-hosts-soap-myth-online-reading-discussion-ed-asner/6562635002/

See the original post:
Holocaust Memorial Center hosts 'Soap Myth' online reading and discussion - The Detroit News

Inverted tulips, juniper trees added to Iran’s national heritage list – Tehran Times

TEHRAN Inverted tulips in the city of Mahneshan as well as two juniper trees in Tarom, northwestern Zanjan province have recently been inscribed on the national heritage list, IRNA reported on Thursday.

Each year in the spring, hillsides and surrounding meadows of the city are teeming with colorful flowers, particularly inverted tulips.

Inverted tulips or Fritillaria is one of the 120,000 identified plants in Iran. There are more than 170 species of tulips in the country. It is said that the tulip has some remedial use for arthritis and rheumatic pains.

Juniper is a very valuable and long-lasting species that grows in mountainous and high areas and has a special place in the legends and myths of Iranian people.

It has long been a symbol of immortality in Iranian culture and it can be seen in historical Iranian miniatures.

Some more three natural properties in the region including rhubarb plain, salt spring, and a Juniper forest were also added to the National Heritage list.

Having an opulent tourist circuit with 24 UNESCO World Heritage sites, of which the vast Hyrcanian Forest and Lut Desert are among the natural properties, Iran seeks to acquire a greater share of the global tourism industry by 2025.

ABU/AFM

Read more:
Inverted tulips, juniper trees added to Iran's national heritage list - Tehran Times

Legacies: Who Is the Most Powerful – Witches, Werewolves or Vampires? – CBR – Comic Book Resources

Out of the three main supernatural beings of The Vampire Diaries universe and the Legacies TV series, which is the most powerful?

The Vampire Diarieswasrichinthe supernatural.Aside from humans, the main threespecies toappear in the series werevampires, werewolves and witches, each with their own strengths and weaknesses. The spin-offs that followed, The Originals and Legacies, took the timeto expand the backgrounds of these creatures, giving them limits and then breaking those limits, creating Hybrids and later Tribrids.

Legacies followsHope Mikaelson, the teenage daughter of Klaus Mikaelson andHayley Marshall, as she attendsThe Salvatore School for the Young and Gifted, a special school run by AlaricSaltzman that takes in young supernatural beings and teaches them how to use their abilities.The school is mostly home to the core triad vampires, witches and werewolves but whichone is the most powerful?

Related:Legacies Has Its First Field Day in Season 3 Premiere Photos

Werewolvesareprobably themost vulnerable of the triad. They possess increased strength, speed and reflexes, but only obtain true power during their full moon transformation. It is only in their wolf form that they can kill or fatally harm their natural enemies, the vampire. Otherwise, they are pretty much defenseless and are no different than enhanced humans. In contrast, vampireswereexplicitlydesignedto be more lethal than werewolvesby the witch, Esther Mikaelson. Whatever the wolves can do, the vampires are supposed to do better and are granted complete free will outside of the moon. However, despite their abilities, vampires also have many limitations.

Confined to night hours, any vampire outside of the originalswithout a daylight ring would burn up in the sun, and despite being immortal, they are oftenkilled quite easily. Vampires can beharmedby a multitude of things including vervain, wood, white oak ash, werewolf venom and even regular man-made poison in rare circumstances. A large theme of The Vampire Diariesuniverse is the balance of nature and order, which is why vampires, being so dangerous, have the most defenses made against them.However, it is this balance that reveals the truly most powerful supernatural being of The Vampire Diaries universe: witches.

See the original post here:
Legacies: Who Is the Most Powerful - Witches, Werewolves or Vampires? - CBR - Comic Book Resources

how is the calendar and when are the long weekends in the year – Explica

After a 2020 marked by the coronavirus, started a new year in which there will be 18 holidays that will seek to shore up tourism, one of the sectors hardest hit by the pandemic.

More than a month in advance, the national government set what will be the three bridge holidays, established in order to promote the activity, through Decree 947/2020, published on November 26.

The standard provided that these will be:

On Monday, May 24, in the prelude to the national day in memory of the May Revolution. On Friday, October 8, in anticipation of the Day of Respect for Cultural Diversity. On Monday, November 22, after the Day of National Sovereignty.

The norm recalls that the Executive Power is empowered to set annually up to three holidays or non-working days destined to promote tourist activity, which must coincide with Monday or Friday.

In the text, it was established that this faculty becomes a policy aimed at boost domestic tourism in the Argentine RepublicAnd, in turn, it was mentioned that those three days are related to helping to reduce the negative effects of seasonality in the tourism sector, trying to distribute them over time.

In addition, there will be 11 fixed holidays, five of which will lead to long weekends:

1 of January New Year). April 2 (Veterans Day and the Fallen in the Malvinas War, and Good Friday). July 9 (Independence Day). February 15 and 16 (Carnival).

Two of the immovable holidays fall on weekends and will not have modifications:

May 1 (Labor Day). 25th December, Christmas).

On the other hand, there will be four portable holidays at the ends of generating long weekends:

Thursday, June 17 (Passage to the Immortality of General Gemes) will be held on Monday, June 21. On Tuesday, August 17 (General Jos de San Martns Passage to Immortality) is moved to Monday, August 16. Tuesday, October 12 (Respect for Cultural Diversity Day) moves to Monday through October 11. Saturday November 20 (National Sovereignty Day) goes to Monday November 22.

January 1: New Years February 15: Carnival February 16: Carnival March 24: National Day of Remembrance for Truth and Justice April 1: Holy Thursday April 2: Veterans Day and the Memorial Day Malvinas War, and Good Friday May 1: Labor Day May 24: Holiday for tourist purposes May 25: Day of the May Revolution June 20: Day of the Immortality of General Manuel Belgrano June 21: Day of the Passage to the Immortality of General Martn de Gemes July 9: Independence Day August 16: Passage to the Immortality of General Jos de San Martn October 8: Holiday for tourist purposes October 11: Day of Respect for the Cultural Diversity November 20: National Sovereignty Day November 22: Holiday for tourism purposes December 8: Immaculate Conception of Mary December 25: Christmas

Visit link:
how is the calendar and when are the long weekends in the year - Explica

Why I Got the Russian Vaccine – The New York Times

MOSCOW A nurse, needle in hand, asked me brusquely if I was ready. I said yes. A quick injection followed, then instructions to wait a half-hour in the hospital corridor for the possibility of anaphylactic shock, which thankfully never came.

Last Monday, I put aside my misgivings and got the first dose of Russias coronavirus vaccine, called Sputnik V, made at a factory outside of Moscow from genetically modified human cold viruses.

Like so much else in Russia, the rollout of Sputnik V was entangled in politics and propaganda, with President Vladimir V. Putin announcing its approval for use even before late-stage trials began. For months, it was pilloried by Western scientists. Like many Russian citizens distrustful of the new vaccine, saying they would wait to see how things turned out before getting it themselves, I had my doubts.

Consider how the rollout went: With the approval back in August, Russian health officials were quick to assert they had won the vaccine race, just as the country had won the space race decades ago with the Sputnik satellite. In fact, at the time, several other vaccine candidates were further along in testing.

A series of misleading announcements followed. The vaccines backers claimed a national inoculation campaign would begin in September, then in November; it ramped up only last month, no earlier than the kickoff of vaccinations in Britain and the United States.

Then came suspicions aired in foreign reporting that the Russian government, already eyed warily in medical matters over accusations of poisoning dissidents and doping Olympic athletes, was now cooking the books on vaccine trial results, perhaps for reasons of national pride or marketing.

As if to outperform the perceived competition, when Pfizer and the German pharmaceutical company BioNTech reported trial results showing more than 91 percent efficacy for their candidate vaccine, the Kremlin-connected financial company backing Sputnik V asserted its trials showed 92 percent efficacy.

When Moderna then reported 94.1 percent efficacy, the Russian company again claimed superiority, saying it achieved 95 percent. Officials later conceded, when the late-stage trials were complete, that Sputnik Vs results showed an efficacy rate of 91.4 percent.

But from the perspective of a recipient, did that matter? The final reported result still offers a nine out of 10 chance of avoiding Covid-19, once the vaccine has taken effect. Skepticism from Western experts focused mostly on the questionable early approval, not the vaccines design, which is similar to the one produced by Oxford University and AstraZeneca.

While public apprehension hasnt completely subsided, and the developers have yet to release detailed data on adverse events observed during the trials, the Russian government has now vaccinated about one million of its own citizens and exported Sputnik V to Belarus, Argentina and other countries, suggesting that any harmful side effects overlooked during trials would by now have come to light.

In the end, the politicized rollout only served to obscure the essentially good trial results what appears to be a bona fide accomplishment for Russian scientists continuing a long and storied practice of vaccine development.

In the Soviet period, tamping down infectious diseases was a public health priority at home and exporting vaccines to the developing world an element of Cold War diplomacy.

While the exact order of vaccine recipients may vary by state, most will likely put medical workers and residents of long-term care facilities first. If you want to understand how this decision is getting made, this article will help.

Life will return to normal only when society as a wholegains enough protection against the coronavirus. Once countries authorize a vaccine, theyll only be able to vaccinate a few percent of their citizens at most in the first couple months. The unvaccinated majority will still remain vulnerable to getting infected. A growing number of coronavirus vaccines are showing robust protection against becoming sick. But its also possible for people to spread the virus without even knowing theyre infected because they experience only mild symptoms or none at all. Scientists dont yet know if the vaccines also block the transmission of the coronavirus. So for the time being, even vaccinated people will need to wear masks, avoid indoor crowds, and so on. Once enough people get vaccinated, it will become very difficult for the coronavirus to find vulnerable people to infect. Depending on how quickly we as a society achieve that goal, life might start approaching something like normal by the fall 2021.

Yes, but not forever. The two vaccines that will potentially get authorized this month clearly protect people from getting sick with Covid-19. But the clinical trials that delivered these results were not designed to determine whether vaccinated people could still spread the coronavirus without developing symptoms. That remains a possibility. We know that people who are naturally infected by the coronavirus can spread it while theyre not experiencing any cough or other symptoms. Researcherswill be intensely studying this question as the vaccines roll out. In the meantime, even vaccinated people will need to think of themselves as possible spreaders.

The Pfizer and BioNTech vaccine is delivered as a shot in the arm, like other typical vaccines. The injection wont be any different from ones youve gotten before. Tens of thousands of people have already received the vaccines, and none of them have reported any serious health problems. But some of them have felt short-lived discomfort, including aches and flu-like symptoms that typically last a day. Its possible that people may need to plan to take a day off work or school after the second shot. While these experiences arent pleasant, they are a good sign: they are the result of your own immune system encountering the vaccine and mounting a potent response that will provide long-lasting immunity.

No. The vaccines from Moderna and Pfizer use a genetic molecule to prime the immune system. That molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oily bubble that can fuse to a cell, allowing the molecule to slip in. The cell uses the mRNA to make proteins from the coronavirus, which can stimulate the immune system. At any moment, each of our cells may contain hundreds of thousands of mRNA molecules, which they produce in order to make proteins of their own. Once those proteins are made, our cells then shred the mRNA with special enzymes. The mRNA molecules our cells make can only survive a matter of minutes. The mRNA in vaccines is engineered to withstand the cell's enzymes a bit longer, so that the cells can make extra virus proteins and prompt a stronger immune response. But the mRNA can only last for a few days at most before they are destroyed.

The Soviet Union and United States cooperated in eliminating smallpox through vaccination. Virology was central to the Soviet Unions biological weapons program, which continued in secrecy long after a 1975 treaty banned the weapons.

In 1959, a husband-and-wife team of Soviet scientists successfully tested the first live polio virus vaccine using their own children as the first trial subjects. That followed a Russian tradition of medical researchers testing potentially harmful products on themselves first.

Last spring, the chief developer of Sputnik V, Aleksandr L. Gintsburg, followed in this custom by injecting himself even before the announcement that animal trials had wrapped up.

Russian promoters have compared the vaccine to the Kalashnikov rifle, simple and effective in its operation. I was even lucky in avoiding some of the common side effects of Sputnik V, such as a raging headache or a fever.

With many of my fears alleviated, another reason I chose to get inoculated with a product of Russian genetic engineering was more basic: It was available. Russian clinics have not been do
gged by the lines or logistical snafus reported at vaccination sites in the United States and other countries.

In Moscow, the best days of winter come in early January as the country slumbers through a weeklong holiday, the traffic thins and the citys bustling chaos gives way to a quiet, snowy beauty. Vaccination sites were also lightly attended.

Russias vaccination campaign began with medical workers and teachers and then expanded. It is now open to people older than 60 or with underlying conditions that render them vulnerable to more severe disease, and to people working in a widening list of professions deemed to be at high risk: bank tellers, city government workers, professional athletes, bus drivers, police officers and, conveniently for me, journalists. Its unclear whether Russias production capacity is sufficient to meet demand long term.

For now, with so many Russians deeply skeptical of their medical system and the vaccine, there is no great clamor for the shot. The first site I visited, while reporting back in December, closed early because so few people had turned up.

In the capital, the vaccine has, paradoxically, appealed to educated people, a group that is traditionally a hotbed of political opposition to Mr. Putin, the chief promoter of the vaccine. When it came to a decision about health, many rolled up their sleeves.

I got the second component of Sputnik in my shoulder, Andrei Desnitsky, an academic at the Institute of Oriental Studies who has been chronicling his experience with vaccination, wrote on Facebook.

To followers posting comments, he said, hysterics in the style of You sold out, you bastard, to the bloody regime and They take us all for idiots, will be deleted.

Like Mr. Desnitsky, I was willing to take my chances. At Polyclinic No. 5 on a snowy morning, I filled out a form asking about chronic diseases, blood disorders or heart ailments. I showed my press pass as proof of my profession. A doctor asked a few questions about allergies. I waited an hour or so for my turn in a beige-tiled hospital corridor.

Sitting nearby was Galina Chupyl, a 65-year-old municipal worker. What did she think of getting vaccinated?

I am happy, of course, she said. Nobody wants to get sick.

I agreed.

Excerpt from:
Why I Got the Russian Vaccine - The New York Times

What the emerging new strain of the Coronavirus means for the vaccine – WATN – Local 24

A local doctor explains what's in the COVID-19 vaccine and how it works.

MEMPHIS, Tenn Concerns about the COVID-19 vaccine remain.

It's the first vaccine without a living virus, but some are concerned over what's in the COVID-19 vaccine.

"This vaccine is the result of, really, some genetic engineering. They are able to sequence the virus, decode it and find the genetic code for just a part of the virus, specifically the spike that is located on the outside of the virus," said Dr. Bruce Randolph of the Shelby County Health Department.

He says that's the part of the virus that attaches to the human cell.

Worried the vaccine arrived too soon?

COVID-19 may have entered American consciousness about 9 months ago, but scientists have studied different forms of the Coronavirus for years.

The variations go back some 10-thousand years.

Researchers are also keeping an eye on a new variant called B-1-17 found in a few states, but not yet in Tennessee.

"This particular virus is five times more easier to transmit than the Coronavirus we are dealing with at the current time," said Randolph.

For example, Randolph explains if COVID-19 takes 100 droplets for infection, this new strain might only take 10.

With 72-thousand COVID cases just reported in Shelby County a new strain would cause great concern.

"If this variant strain hit Shelby County those number could be as much as 5 times higher," said Randolph.

Researchers believe the current vaccine will provide immunity for that new strain.

the Memphis-Shelby County task force are urging everybody to get educated, talk to your doctor, get vaccinated and keep up with your card.

"You would be able to go wherever and present your card and say I need my second dose and the provider would know exactly when you last received, if it's indeed time for you to receive your second dose and what vaccine you received because you shouldn't mix them."

Read the original post:
What the emerging new strain of the Coronavirus means for the vaccine - WATN - Local 24

Could We Populate Another Planet With Genetically Modified Organisms? – Gizmodo

Illustration: Benjamin Currie/Gizmodo

Earlier this year, a research team made waves by suggesting that we should disseminate Earths microbes on Mars in a preemptive effort to foster a climate hospitable to human life. To the anti-contamination school of celestial thought, this was heresy; to the most others, this was an obscure theoretical squabble over an issue theyd never heard about. Still, given that our descendants may well spend their most productive years on Mars, its worth trying to grasp these early, pre-colonial debates before they assume life-or-death urgency. To that end, for this weeks Giz Asks weve posed a two-parter to a number of relevant experts. First: Could we populate another planet with genetically modified organisms? Second: Should we?

Associate Professor, Anthropology, York University, whose research focuses on the social and ethical aspects of space exploration, among other things

We probably could; we probably shouldnt. But first, its worth asking: whos we?

Discussion of space and the future often involves a rhetorical we that encompasses all humanity or our species. But its time to think differently about space. There is no big we here. For the foreseeable future, only a very few human beings will have the capability to launch or act in spaceand only a very few human beings have the ability to genetically modify other organisms. And obviously, that tiny contingent of humans invents and develops these technologies with the general intention of using them.

That tiny contingent of humans does not include me. I have opinions. But I dont have a vote. And thats true for the vast majority of people reading this. That matters, because when a space agency, space advocacy group, Elon Musk, or Jeff Bezos, etc., says We should do X or Y in space theyre using traditional rhetoric that encourages audiences to think that we (the rest of humanity) are a part of what theyre doing. Clarity on this matters a lot now, as multilateralism is either faltering or collapsing, the capabilities of private actors are accelerating, and the likelihood of unilateral actions increases. There are a multitude of different interests in space, and a multitude of ideologies and capabilitiesnot one we.

Anyway, in theory, yes, some humans could introduce some genetically modified organisms onto another planet. (Full-on terraforming is much less feasible.) Not all planets would be suitable, but some might be. Human technology cannot yet physically reach the myriad planets outside our solar system, but miniscule interstellar probes carrying dormant microbial payloads and pointed at exoplanets are theoretically possible. But for the moment, the most likely targets would be the planets (and moons) in our own solar system. So:

Should some humans populate a world in our solar system with GM organisms? Nooooooooo. At the very least, not yet. Reason #1: many would regard this as a breach of the Outer Space Treaty. Reason #2: some of those worlds might have life already, and its much better to find it and study it thoroughly first. Reason #3: Perhaps other worlds have their own intrinsic value regardless of their liveliness. Worth considering, at least.

Further away: should some humans populate an exoplanet with GM organisms? A louder Noooooooooooooo. Louder because theres an unnerving asymmetry: it could be faster/easier to send a payload-laden micro-probe to an exoplanet than to study the exoplanet thoroughly first. Also, human beings are not going to exoplanets anytime soonif everwhich negates a main justification for doing this kind of bioengineering.

G/O Media may get a commission

Senior Scientist, SETI Institute

Take Mars, Europa, and Enceladuseach of which appear to have water tucked out of the way, below thick ice layers (although not always hiddenthere are plumes). We probably could modify an Earth organism, or suite of organisms, to live in such places for some limited period of time, but I couldnt guarantee you could populate one of those places with GMOs. Unless you were tremendously lucky, the Earth organisms might eat all of the minerals in reach, and then stage a massive die-off that would be tremendously yucky and pointless. And if you were that lucky, there might be native organisms that would just eat your GMO additions and yield a polite burp of methane and leave it at that. Right now we dont know enough to do something useful with GMOs at any alien place (and only a few on Earth).

There are lots of ways in which we are too ignorant to do anything useful with this scheme, and of course not knowing how ignorant we are is one of them. We do not need to give up on a search for life elsewhere in this solar system just because some microbiologists have a tool and no patience. And we dont need to take shortcuts in pursuing such a search so that we lose that scientific pursuit just because it is hard to do without inadvertent (let alone purposeful) contamination of the best sites.

Professor of Planetary Habitability and Astrobiology at Technical University Berlin, President of the German Astrobiology Society, and Co-author of The Cosmic Zoo: Complex Life on Many Worlds

I dont think were there yet, in two senses. We dont know the environmental conditions of other planets well enough, and we dont know how to optimally tune the genetic code of an organism to thrive in that extraterrestrial environment. The only planet where I see this as a possibility in the near future is Mars, which we know best of all the planets and moons in our Solar System.

But even if we can do it, I dont think we should. It would be a very human-centric approach. Instead, we should try to explore the diversity of life that may exist on other planetary targets. In regard to Mars, that would mean exploring whether indigenous (microbial) life exists, and if so, studying how it is different from life on Earth. (Even if there is a common origin, evolution in the different planetary environments would still have resulted in significant organismic changes.)

Mars (and any other planet or moon potentially harboring life) has many microenvironments that may contain life; to conclusively prove that there is no indigenous life at all, anywhere on the planet, may be close to impossible, at least for the foreseeable future (and especially given our current ignoranceafter all, we only know about one type of life). As long as the possibility of indigenous life cannot be excluded, populating Mars or any other planet with genetically modified organisms is out of the question.

If we encounter a habitable planetand one which we know for sure is uninhabitedthe question becomes harder to answer. We can come to that when the situation ariseswhich it wont for a very long time.

Professor and Principle Investigator of the Ohio Musculoskeletal & Neurological Institute and Emeritus Professor of Space Biology at Nottingham University

Indeed we could. We have the capability to land robots on other planets. Currently we sterilize these to prevent accidentally contaminating other planets with microscopic life forms. If we wanted to not sterilize or deliberately send microscopic life to other planets, this is fairly easy to do. Similarly, labs on Earth routinely make and use genetically modified microscopic life forms. Thus, it is also fairly easy to send GMO microscopic life forms to other planets.

Whether we should is the more difficult question. Who benefits from doing this, and who loses out? Do the benefits outweigh the losses? If this is done to allow human habitation of another planet, then potentially all of humanity gainswhereas those aspects of planetary science that want/need to study a natural planet lose out. If this is done to allow for the commercial/financial gain of a few, does that outweigh the loss to science?

Assistant Professor of Astronomy and Molecular and Cellular Biology at the University of Arizona

It depends on the planet. An exoplanet around a star system is probably out of reach with current technology.

If
the candidate planet is in our solar system, such as Marsperhaps. It becomes a question of: For how much, or how long, are you willing to provide technological assistance to create a habitable volume elsewhere? The engineered organisms will most likely be severely restricted in the range of places they can inhabit. So far as we know, no amount of genetic engineering will enable terrestrial organisms to survive under freezing temperature and extreme soil oxidation conditions, such as those found in the Martian environment.

Subsurface ocean worlds such as Enceladus or Europa might work, but we havent precisely characterized their habitability, and it is difficult to foresee how the organisms would be delivered there if the shell of ice is kilometers thick.

That being said, genetically engineering organisms and evolving them under various conditions may allow us to understand the limits of life here on Earth.

Do you have a burning question for Giz Asks? Email us at tipbox@gizmodo.com.

More:
Could We Populate Another Planet With Genetically Modified Organisms? - Gizmodo

‘The Pattern Seekers’: What autism can tell us about the evolutionary tipping point that made us human – Genetic Literacy Project

[In The Pattern Seekers: How Autism Drives Human Invention, psychologist Simon] Baron-Cohen argues that humans split off from all other animals to become the scientific and technological masters of our planet because we evolved a unique piece of mental equipment that he calls the Systemizing Mechanism While everyone has a Systemizing Mechanism, its tuned especially high in people who are inventors and in those drawn to fields like science, engineering, music, competitive sports, high-level business and often, too, in people with autism.

Heres how the mechanism works: Humans alone observe the world and ask questions that demand why, how and what They use those patterns to build theories, which they then repeatedly test, looking always for systems to further employ and exploit.

As Baron-Cohen describes it, the Systemizing Mechanism is so all-powerful, it explains evolutionary change, historic progress and individual excellence including, for example, the ancient shift from simple to complex tool use, the invention of the light bulb and the late Kobe Bryants highly regimented training schedule. Its true, all these scenarios can be described as looping sequences of if-and-then reasoning. But its a much greater leap to show that this is the main engine of evolution, or that it demonstrates how human brains work in real time, or that the two things have much in common.

[Editors note: Find The Patter Seekers: How Autism Drives Human Invention here.]

Read the original post

View post:
'The Pattern Seekers': What autism can tell us about the evolutionary tipping point that made us human - Genetic Literacy Project

Global CRISPR Technology Market Report 2020: COVID-19 Growth and Change – Market is Expected to Recover to Reach $1.55 Billion in 2023 – Forecast to…

DUBLIN, Jan. 6, 2021 /PRNewswire/ -- The "CRISPR Technology Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

CRISPR Technology Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global crispr technology market.

Major players in the CRISPR technology market are Thermo Fisher Scientific, GenScript Biotech Corporation, CRISPR Therapeutics AG, Editas Medicine, Horizon Discovery Plc., Integrated DNA Technologies, Inc. (Danaher), Origene Technologies, Inc., Transposagenbio Biopharmaceuticals (Hera Biolabs), Intellia Therapeutics Inc., and GeneCopoeia, Inc.

The global CRISPR technology market is expected to increase from $0.76 billion in 2019 to $0.92 billion in 2020 at a compound annual growth rate (CAGR) of 20.91%. The exponential growth is mainly due to the COVID-19 outbreak that has led to the research for drugs for COVID-19 with gene-editing using CRISPR technology. The market is expected to reach $1.55 billion in 2023 at a CAGR of 19.13%.

The CRISPR technology market consists of sales of CRISPR technology products and services which is a gene-editing technology that allows researchers to alter DNA sequences and modify gene function. The revenue generated by the market includes the sales of products such as design tools, plasmid & vector, Cas9 & gRNA, libraries & delivery system products and services that include design & vector construction, screening and cell line engineering.

These products and services are used in genome editing/genetic engineering, genetically modifying organisms, agricultural biotechnology and others which include gRNA database/gene library, CRISPR plasmid, human stem cell & cell line engineering by end-users. The end-users include pharmaceutical & biopharmaceutical companies, biotechnology companies, academic & research institutes and contract research organizations.

North America was the largest region in the CRISPR technology market in 2019. Europe was the second-largest region in the CRISPR technology market in 2019.

In 2019, Cardea Bio Inc., a US-based biotechnology infrastructure company that manufactures biology-gated transistors (Cardean transistors) that utilizes biocompatible graphene instead of silicon and replaces optical signal observations with direct electrical molecular signal analysis, merged with Nanosens Innovations, Inc. The merger is aimed at accelerating the development of the genome sensor that combines Nanosens' CRISPR-Chip technology with Cardea's graphene biosensor infrastructure and is the first DNA search engine globally that runs on CRISPR-Chip technology. Nanosens will be operating as a subsidiary of Cardea Bio. Nanosens Innovations, Inc. is a US-based biotechnology company that develops CRISPR-Chip and FEB technology.

The CRISPR technology market covered in this report is segmented by product type into design tools; plasmid and vector; CAS9 and G-RNA; delivery system products. It is also segmented by application into genome editing/ genetic engineering; genetically modified organisms; agricultural biotechnology; others and by end-user into industrial biotech; biological research; agricultural research; therapeutics and drug discovery.

Stringent government regulations are expected to retard the growth of the CRISPR technology market during the period. There is no existence of internationally agreed regulatory framework for gene editing products and countries are in the process of evaluating whether and to what extent current regulations are adequate for research conducted with gene editing and applications and products related to gene editing. In July 2018, the Court of Justice of the European Union ruled that it would treat gene-edited crops as genetically modified organisms, subject to stringent regulation.

In April 2019, the Australian government stated that the Office of the Gene Technology Regulator (OGTR) will regulate only the gene-editing technologies that use a template, or that insert other genetic material into the cell. According to an article of 2020, in India, as per the National Guidelines for Stem Cell Research, genome modification including gene-editing by CRISPR-Cas9 technology of stem cells, germ-line stem cells or gamete and human embryos is restricted only to in-vitro studies. Thus, strict regulations by the government present a threat to the growth of the market.

Several advancements in CRISPR technology are trending in the market during the period. Advancements in technology will help in reducing errors, limiting unintended effects, improving the accuracy of the tool, widening its applications, developing gene therapies and more. In 2019, a study published in Springer Nature stated the development of an advanced super-precise new CRISPR tool that allows researchers more control over DNA changes. This tool seems to have the capability of providing a wider variety of gene edits which might potentially open up conditions that have challenged gene-editors.

Also, in 2020, another study in Springer Nature stated that researchers have used enzyme engineering to boost the accuracy of the technique of error-prone CRISPR-Cas9 system to precisely target DNA without introducing as many unwanted mutations. The advancements in CRISPR technology will result in better tools that are capable of providing better outcomes.

The application of CRISPR technology as a diagnostic tool is expected to boost the market during the period. The Sherlock CRISPR SARS-CoV-2 kit is the first diagnostic kit based on CRISPR technology for infectious diseases caused due to COVID-19. In May 2020, FDA announced the emergency use authorization to the Sherlock BioSciences Inc's Sherlock CRISPR SARS-CoV-2 kit which is a CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test.

This test helps in specifically targeting RNA or DNA sequences of the SARS-CoV-2 virus from specimens or samples such as nasal swabs from the upper respiratory tract and fluid in the lungs from bronchoalveolar lavage specimens. This diagnostic kit has high specificity and sensitivity and does not provide false negative or positive results. Widening the application of CRISPR technology for the diagnosis of infectious diseases will increase the demand for CRISPR technology products and services.

Key Topics Covered:

1. Executive Summary

2. CRISPR Technology Market Characteristics

3. CRISPR Technology Market Size And Growth

3.1. Global CRISPR Technology Historic Market, 2015 - 2019, $ Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global CRISPR Technology Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. CRISPR Technology Market Segmentation

4.1. Global CRISPR Technology Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.2. Global CRISPR Technology Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.3. Global CRISPR Technology Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5. CRISPR Technology Market Regional And Country Analysis 5.1. Global CRISPR Technology Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion 5.2. Global CRISPR Technology Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/vnvkue

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-
0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Follow this link:
Global CRISPR Technology Market Report 2020: COVID-19 Growth and Change - Market is Expected to Recover to Reach $1.55 Billion in 2023 - Forecast to...

Global Biotechnology Services Market Report 2020: Market to Grow at a CAGR of 5% from 2019 to 2020 Due to COVID-19 and Increase in R&D Activities -…

DUBLIN, Jan. 8, 2021 /PRNewswire/ -- The "Biotechnology Services Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Biotechnology Services Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global biotechnology services market.

Major players in the biotechnology services market are Novartis, Fisher BioService, Pfizer, Novo Nordisk, BioAlps, Precision for Medicine, Sartorius and Aldevron.

The global biotechnology services market is expected to increase from $142.92 billion in 2019 to $150.06 billion in 2020 at a compound annual growth rate (CAGR) of 5.0%. The growth is mainly due to the COVID-19 outbreak that has led to an increase in research and development activities. The market is expected to grow further and reach $210.96 billion in 2023 at a CAGR of 12.03%. Biotechnology services is the second-largest sector after biopharmaceuticals which is anticipated to emerge significantly due to increasing research and development activities.

The biotechnology services market consists of the sales of biotechnology services and related goods by entities (organizations, sole traders and partnerships) that engage in conducting research and experimental development in biotechnology. Only goods and services traded between entities or sold to end consumers are included.

North America was the largest region in the biotechnology services market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period.

In May 2018, Illumina, a US-based biotechnology company serving in research, clinical and applied markets, acquired Edico Genome for an undisclosed amount. The acquisition is expected to reduce sequencing data acquisition. Edico Genome's Bio-IT platform DRAGEN uses field-programmable gate array (FPGA) technology with software algorithms and helps in reducing data footprint and time for results. The DRAGEN platform complements Illumina's sequencing portfolio and helps the customer in reducing investment in IT infrastructure and improve overall efficiency.

The biotechnology services market covered in this report is segmented by service into prevention and disease control; public engagement activities; health education and research; food biotechnology services; donor recruitment; tissue collection; cell processing and isolation; research and development. It is also segmented by industry into clinical research organizations (CROs); contract manufacturers organizations (CMOs); contract research and manufacturing services (CRAMs) and by area of application into pharmaceutical; biotechnological; academic; clinical trial; healthcare sector.

The risk related to genetic data is anticipated to limit the growth of the biotechnology services market. The biotechnological approach of transferring specially created genes for modification in characteristics to create genetically modified organisms (GMOs) has always been considered a threat to human and environmental health. According to the report of the World Conservation Union, there are numerous environmental risks likely to occur by the use of GMOs, which include interbreeding, antibiotic resistance, impact on the ecosystem, creation of new or worse viruses, competition with natural species, unpredictable and unintended effects and ethical concerns.

Collaborations and partnerships between industry players are a growing trend in the field of biotech services. In Dec 2019, Interpace Pharma, a subsidiary of Interpace Biosciences, dealing in pharmacogenomics testing, genotyping and biorepository services, collaborated with Genecast Biotechnology Co. Ltd for jointly developing, promoting, and offering translational studies and clinical trial solutions to the industry. This partnership is expected to benefit pharmaceutical and biotech companies to accelerate their biomarker-driven drug development and precision medicine.

The increasing pervasiveness of conditions like hepatitis B, diabetes and cancer is driving the research in biotechnology. Biotechnology uses research tools from biology and chemistry to study the genetic material of bacteria and viruses to check the disease-producing agent. Oncology research is most prominent among biopharma companies. Stem cell treatment, using a monoclonal antibody for therapy and genome sequencing is progressing in medical applications. The sales of global biotech drugs are expected to reach $284 billion in 2020.

According to Data-Driven Investor, all sectors of biotech companies together spend 20% of their budget on research and development, accounting for nearly $750 billion in 2018. Therefore, the rising pervasiveness of diseases and huge expenses on R&D is predicted to contribute to the growth of the biotechnology services market.

Key Topics Covered:

1. Executive Summary

2. Biotechnology Services Market Characteristics

3. Biotechnology Services Market Size and Growth 3.1. Global Biotechnology Services Historic Market, 2015 - 2019, $ Billion 3.1.1. Drivers of the Market 3.1.2. Restraints on the Market 3.2. Global Biotechnology Services Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion 3.2.1. Drivers of the Market 3.2.2. Restraints on the Market

4. Biotechnology Services Market Segmentation 4.1. Global Biotechnology Services Market, Segmentation by Service, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Story continues

Prevention and Disease Control

Public Engagement Activities

Health Education and Research

Food Biotechnology services

Donor Recruitment

Tissue Collection

Cell Processing and Isolation

Research & Development

4.2. Global Biotechnology Services Market, Segmentation by Industry, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Clinical Research Organizations (CROs)

Contract Manufacturers Organizations(CMOs)

Contract Research and Manufacturing Services (CRAMS)

4.3. Global Biotechnology Services Market, Segmentation by Area of Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Pharmaceutical

Biotechnological

Academic

Clinical Trial

Healthcare Sectors

5. Biotechnology Services Market Regional and Country Analysis 5.1. Global Biotechnology Services Market, Split by Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Companies Mentioned

Novartis

Fisher BioService

Pfizer

Novo Nordisk

BioAlps

Precision for Medicine

Sartorius

Aldevron

For more information about this report visit https://www.researchandmarkets.com/r/oagrsu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-biotechnology-services-market-report-2020-market-to-grow-at-a-cagr-of-5-from-2019-to-2020-due-to-covid-19-and-increase-in-rd-activities---forecast-to-2030-301203342.html

SOURCE Research and Markets

The rest is here:
Global Biotechnology Services Market Report 2020: Market to Grow at a CAGR of 5% from 2019 to 2020 Due to COVID-19 and Increase in R&D Activities -...

Sana Biotechnology Announces Appointments to its Board of Directors – BioSpace

SEATTLE, Jan. 8, 2021 /PRNewswire/ -- Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today that Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA, have been appointed to the Sana Board of Directors.

"Josh, Alise, and Michelle all share a passion and commitment to our long-term vision of engineering cells to make medicines that improve the lives of patients," said Sana President and CEO Steve Harr. "The diversity of their experiences, backgrounds, and expertise will be critical to our strategy, decision-making, risk-management, and governance. I look forward to working with them to continue to build Sana."

Dr. Bilenker is CEO of Loxo Oncology at Lilly, a research and development group of Eli Lilly. He joined Eli Lilly when the company acquired Loxo Oncology, Inc., where he had been founding CEO. Prior to Loxo, Dr. Bilenker joined Aisling Capital LLC in April 2006 and has served as an Operating Partner since November 2013.Previously, he served as a medical officer at the U.S. Food and Drug Administration in the Office of Oncology Drug Products. Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins University School of Medicine and his A.B. degree in English from Princeton University.

Dr. Reicin is CEO and President of Tectonic Therapeutic, Inc.Previously, Dr. Reicin was President, Global Clinical Development at Celgene Corporation, overseeing the clinical development organization. Prior to Celgene, Dr. Reicin was the Head of Global Clinical Development at EMD Serono. Prior to joining EMD Serono, Dr. Reicin served as Vice President, Program and Pipeline Leadership, Oncology at Merck and Co. Before joining Merck, Dr. Reicin was a faculty member at Columbia Medical School, and a physician and researcher at Columbia Presbyterian Hospital. She received her B.S. in biochemistry from Barnard College of Columbia University and her M.D. from Harvard Medical School, where she was enrolled in the Health Sciences and Technology program with Massachusetts Institute of Technology.

Ms. Seitz is Chairman andCEO of Russell Investments. Previously, Ms. Seitz spent 22 years at William Blair, serving 16 years on the firm's board and as CEO of William Blair Investment Management. She is a member of Challenge Seattle, an alliance of CEOs from the region's largest employers dedicated to ensuring that Seattle continues to thrive as one of the most globally competitive regions in the world. Ms. Seitz is on the board of the Washington Roundtable and on the Dean's Council at the Indiana University Kelley School of Business, where she graduated with a B.S. in accounting. She is a Chartered Financial Analyst (CFA) and past board member of The Financial Accounting Foundation (FAF), the governance board of the Financial Accounting Standards Board (FASB) and the Governmental Accounting Standards Board (GASB).

About Sana

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are more than 250 people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, and South San Francisco.

Contactcontact@sana.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/sana-biotechnology-announces-appointments-to-its-board-of-directors-301203167.html

SOURCE Sana Biotechnology, Inc.

Read more from the original source:
Sana Biotechnology Announces Appointments to its Board of Directors - BioSpace

Felix Biotechnology announces initiation of the CYPHY Phase 1/2 study at Yale for its lead asset targeting P. aeruginosa infections – PRNewswire

SAN FRANCISCO, Jan. 7, 2021 /PRNewswire/ --Felix Biotechnology today announced the initiation of CYPHY, a Phase 1/2 investigator-initiated single center trial at Yale University for targeted phage therapy YPT-01 in the treatment of chronic P. aeruginosa infections in cystic fibrosis. This double-blind, placebo-controlled study (NCT 04684641) will assess the safety and efficacy of YPT-01added to standard antimicrobial therapy in 36 patients. CYPHY will also assess the ability of YPT-01 to reduce the virulence and antibiotic-resistance of P. aeruginosa, improving patient outcomes and re-enabling use of traditional antibiotics against multi-drug resistant strains. The lead investigator for this study, Dr. Jon Koff, Associate Professor and Director of Yale's Adult Cystic Fibrosis Program, is supported by an academic grant from the Cystic Fibrosis Foundation.

"This is a fantastic opportunity to show how effective phage therapy can be when deployed in an evolutionary framework. We know that pathogens evolve resistance to any antibiotic or therapy we use, so our approach turns that to our advantage," said Dr. Paul Turner, Professor of Ecology and Evolutionary Biology, co-inventor of YPT-01, and co-founder of Felix Biotechnology. "By targeting phage to mechanisms of virulence, we ensure that if pathogens evolve resistance to phage, they lose traits that make them effective pathogens, putting them in an evolutionary Catch-22."

"Phage therapies have been used for over a century but for various reasons clinical trials to demonstrate their efficacy have been unsuccessful. In designing CYPHY, we learned from those studies to develop best practices for a truly blinded, randomized, placebo-controlled phage therapy trial. But most importantly, this study aims to help patients," said Dr. Ben Chan, Research Scientist and co-inventor of YPT-01.

YPT-01 is an inhaled phage therapy that targets and kills P. aeruginosa and has been administered to 12 patients with chronic and multi-drug resistant infections via emergency INDs. The phages comprising YPT-01 were selected based on safety, efficacy against clinical isolates of P. aeruginosa, and unique abilities to reduce virulence and antibiotic resistance. This evolutionary biology approach benefits patients and physicians by effectively treating infections, reducing the threat of subsequent infections, and ensuring a treatment option is always available. It may also benefit healthcare systems and public health overall by driving reductions in virulence and antibiotic resistance in hospital pathogen populations, counteracting decades of selection by traditional antibiotics.

Felix Biotechnology holds an exclusive license from Yale for YPT-01. "Our key focus at Felix Biotechnology is to help patients and we are very excited to see this therapy move into a 36 patient controlled and blinded trial," said Rob McBride, Felix Biotechnology's CEO. "If the data from this trial reflect earlier human data showing safety and efficacy, we will focus on moving this asset into a larger commercial trial as soon as possible."

About YPT-01YPT-01 is an inhaled phage therapy that targets and kills P. aeruginosa and has been administered to 12 patients with chronic and multi-drug resistant infections via emergency INDs. The phages comprising YPT-01 kill P. aeruginosa and drive trade-offs in virulence and antibiotic resistance in any residual pathogen, reducing pathogen threat and improving patient outcomes.

About Felix BiotechnologyFelix Biotechnology is a clinical stage biotherapeutics company focused on helping patients who can't wait by developing and deploying non-traditional antibiotics targeting urgent microbial threats. Felix's engineering and discovery platforms, built on technology from Yale University and UC Berkeley, generate therapies that overcome the key limitations of traditional phage therapy to develop generalized solutions that kill targeted bacterial infections while preserving healthy microbiome function. Felix is a seed stage company funded by multiple investors, including Y Combinator, Illumina Accelerator and Point72 Ventures.

SOURCE Felix Biotechnology, Inc.

https://www.felixbt.com

View original post here:
Felix Biotechnology announces initiation of the CYPHY Phase 1/2 study at Yale for its lead asset targeting P. aeruginosa infections - PRNewswire

Nature Biotechnology publishes research on wheat resistant to rust fungal diseases – Fence Post

Nature Biotechnology has published research partially funded by The 2Blades Foundation on the development of a new wheat variety that shows exceptional resistance to wheat stem rust.

Stem rust is among the worlds most devastating plant diseases, with records of stem rust pandemics dating back over 2000 years. The stem rust pathogen Puccinia graminis is capable of completely destroying a crop of wheat in a matter of weeks.

The most effective and environmentally benign way to control wheat rust is through the use of genetic resistance. The recurring threat to the wheat crop had been managed successfully in the 1960s through Norman Borlaugs breeding of the wheat varieties introduced in the Green Revolution. But rust pathogen races have now evolved to overcome that resistance and once again the disease threatens harvests.

The research team developing the new resistance to wheat rust was led by Dr. Mick Ayliffe at the Canberra laboratories of Australias national science agency CSIRO, who used genetic technologies to build and insert a stack of five rust resistance genes into a single location in the genome of a common wheat variety. The resulting new wheat variety shows exceptional resistance to stem rust.

The result represents an advance over conventional wheat breeding methods where the development of an equivalent disease-resistant wheat would require a long succession of crosses, and the resulting resistance could be lost in subsequent crosses.

In this new approach individual resistance genes are assembled rapidly into a single stack and introduced into a chosen wheat line. This not only eliminates time-consuming breeding efforts, it also ensures that the desirable trait (determined by multiple genes) will not be lost in subsequent breeding. This study targeted wheat stem rust, but the same technology is being used to create durable resistance for wheat stripe and leaf rust diseases which also attack wheat crops.

In future, gene stacks could be prepared with genome-editing tools to develop improved crops that may be considered non-GM (non-genetically modified) in some countries, such as the U.S.

In addition to the CSIRO group, the international consortium working on this program has included researchers from University of Minnesota, Aarhus University, The John Innes Centre in the UK, USDA, and Xinjiang University.

Wheat provides roughly 20 percent of calories and protein for human nutrition worldwide and is the third largest crop grown in the United States.

The most effective and environmentally sound way to defend against wheat rust diseases is through the deployment of resistance genes in wheat varieties. This is particularly important in developing countries where the fungicides used to combat rust disease may be expensive or unavailable.

International adoption of rust-resistant wheat varieties is essential since rust fungi produce trillions of spores that can be carried by winds for thousands of miles even across oceans thus infecting vulnerable wheat crops.

Dr Ayliffes research was supported The 2Blades Foundations continuing program on the control of wheat diseases which was started in 2008.

The 2Blades Foundation, based in Evanston, Ill., is a 501(c)(3) charitable organization dedicated to the discovery, advancement, and delivery of durable disease resistance in crops. 2Blades establishes and manages development programs addressing significant unsolved crop disease problems in collaboration with leading research institutions around the world and at the 2Blades Group in The Sainsbury Laboratory, Norwich, UK.

Visit 2Blades website at 2blades.org and follow us on twitter @2blades.

2Blades Foundation

Follow this link:
Nature Biotechnology publishes research on wheat resistant to rust fungal diseases - Fence Post

G&E Herbal Biotechnology (GTSM:4911) Is In A Strong Position To Grow Its Business – Simply Wall St

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

So, the natural question for G&E Herbal Biotechnology (GTSM:4911) shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

Check out our latest analysis for G&E Herbal Biotechnology

A company's cash runway is calculated by dividing its cash hoard by its cash burn. When G&E Herbal Biotechnology last reported its balance sheet in September 2020, it had zero debt and cash worth NT$121m. In the last year, its cash burn was NT$9.2m. So it had a very long cash runway of many years from September 2020. Even though this is but one measure of the company's cash burn, the thought of such a long cash runway warms our bellies in a comforting way. The image below shows how its cash balance has been changing over the last few years.

In our view, G&E Herbal Biotechnology doesn't yet produce significant amounts of operating revenue, since it reported just NT$24m in the last twelve months. Therefore, for the purposes of this analysis we'll focus on how the cash burn is tracking. The 71% reduction in its cash burn over the last twelve months may be good for protecting the balance sheet but it hardly points to imminent growth. Admittedly, we're a bit cautious of G&E Herbal Biotechnology due to its lack of significant operating revenues. We prefer most of the stocks on this list of stocks that analysts expect to grow.

There's no doubt G&E Herbal Biotechnology's rapidly reducing cash burn brings comfort, but even if it's only hypothetical, it's always worth asking how easily it could raise more money to fund further growth. Companies can raise capital through either debt or equity. Many companies end up issuing new shares to fund future growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

G&E Herbal Biotechnology's cash burn of NT$9.2m is about 0.5% of its NT$1.8b market capitalisation. That means it could easily issue a few shares to fund more growth, and might well be in a position to borrow cheaply.

As you can probably tell by now, we're not too worried about G&E Herbal Biotechnology's cash burn. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. And even its cash burn reduction was very encouraging. Looking at all the measures in this article, together, we're not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. Taking a deeper dive, we've spotted 3 warning signs for G&E Herbal Biotechnology you should be aware of, and 2 of them are a bit unpleasant.

Of course G&E Herbal Biotechnology may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

PromotedWhen trading G&E Herbal Biotechnology or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

More here:
G&E Herbal Biotechnology (GTSM:4911) Is In A Strong Position To Grow Its Business - Simply Wall St

Is Matinas BioPharma Holdings Inc (MTNB) The Right Choice in Biotechnology? – InvestorsObserver

Matinas BioPharma Holdings Inc (MTNB) is around the top of the Biotechnology industry according to InvestorsObserver. MTNB received an overall rating of 79, which means that it scores higher than 79 percent of all stocks. Matinas BioPharma Holdings Inc also achieved a score of 95 in the Biotechnology industry, putting it above 95 percent of Biotechnology stocks. Biotechnology is ranked 26 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Matinas BioPharma Holdings Inc (MTNB) stock has fallen -6.69% while the S&P 500 has risen 0.33% as of 3:17 PM on Friday, Jan 8. MTNB has fallen -$0.11 from the previous closing price of $1.57 on volume of 5,656,629 shares. Over the past year the S&P 500 is up 16.55% while MTNB has fallen -23.04%. MTNB lost -$0.12 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Matinas BioPharma Holdings Inc (MTNB) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

See the article here:
Is Matinas BioPharma Holdings Inc (MTNB) The Right Choice in Biotechnology? - InvestorsObserver

Is BioXcel Therapeutics Inc (BTAI) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

BioXcel Therapeutics Inc (BTAI) is around the top of the Biotechnology industry according to InvestorsObserver. BTAI received an overall rating of 85, which means that it scores higher than 85 percent of all stocks. BioXcel Therapeutics Inc also achieved a score of 98 in the Biotechnology industry, putting it above 98 percent of Biotechnology stocks. Biotechnology is ranked 26 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

BioXcel Therapeutics Inc (BTAI) stock is lower by -3.89% while the S&P 500 is up 0.33% as of 3:19 PM on Friday, Jan 8. BTAI is down -$2.14 from the previous closing price of $54.95 on volume of 485,305 shares. Over the past year the S&P 500 is higher by 16.55% while BTAI is up 330.75%. BTAI lost -$3.37 per share the over the last 12 months.

Click Here to get the full Stock Score Report on BioXcel Therapeutics Inc (BTAI) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Go here to read the rest:
Is BioXcel Therapeutics Inc (BTAI) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver